EVALUATION OF D-PENICILLAMINE IN PRIMARY SCLEROSING CHOLANGITIS

D-青霉胺治疗原发性硬化性胆管炎的评价

• 批准号: 3786821
• 负责人: NICHOLAS F LARUSSO
• 金额: --
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3786821
• 关键词: biliary tract disorder; biliary tract disorder chemotherapy; biochemistry; clinical trials; drug screening /evaluation; histology; human subject; human therapy evaluation; penicillamine; placebos; radiography; sclerosis

To determine the efficacy of D-Penicillamine in the treatment of primary sclerosing cholangitis, 70 pts have been entered into a double blind controlled trial comparing placebo vs 750 mg of D-Penicillamine and have been followed annually by clinical, biochemical, hepatic, histologic, and radiologic criteria.

确定D-青霉胺治疗原发性 硬化性胆管炎，70例患者已进入双盲 对照试验比较安慰剂与750毫克D-青霉胺， 每年都有临床，生化，肝脏， 组织学和放射学标准。